Why Astra won’t find bladder cancer domination easy
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.